IRIS Accounts Production v25.1.3.33 05948662 director 1.10.23 30.9.24 30.9.24 false true false false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh059486622023-09-30059486622024-09-30059486622023-10-012024-09-30059486622022-09-30059486622022-10-012023-09-30059486622023-09-3005948662ns15:EnglandWales2023-10-012024-09-3005948662ns14:PoundSterling2023-10-012024-09-3005948662ns10:Director12023-10-012024-09-3005948662ns10:PrivateLimitedCompanyLtd2023-10-012024-09-3005948662ns10:SmallEntities2023-10-012024-09-3005948662ns10:AuditExempt-NoAccountantsReport2023-10-012024-09-3005948662ns10:SmallCompaniesRegimeForDirectorsReport2023-10-012024-09-3005948662ns10:SmallCompaniesRegimeForAccounts2023-10-012024-09-3005948662ns10:FullAccounts2023-10-012024-09-300594866212023-10-012024-09-3005948662ns10:OrdinaryShareClass12023-10-012024-09-3005948662ns10:CompanySecretary12023-10-012024-09-3005948662ns10:RegisteredOffice2023-10-012024-09-3005948662ns5:CurrentFinancialInstruments2024-09-3005948662ns5:CurrentFinancialInstruments2023-09-3005948662ns5:Non-currentFinancialInstruments2024-09-3005948662ns5:Non-currentFinancialInstruments2023-09-3005948662ns5:ShareCapital2024-09-3005948662ns5:ShareCapital2023-09-3005948662ns5:RetainedEarningsAccumulatedLosses2024-09-3005948662ns5:RetainedEarningsAccumulatedLosses2023-09-3005948662ns5:NetGoodwill2023-10-012024-09-3005948662ns5:IntangibleAssetsOtherThanGoodwill2023-10-012024-09-3005948662ns5:FurnitureFittings2023-10-012024-09-3005948662ns5:NetGoodwill2023-09-3005948662ns5:NetGoodwill2024-09-3005948662ns5:NetGoodwill2023-09-3005948662ns5:FurnitureFittings2023-09-3005948662ns5:FurnitureFittings2024-09-3005948662ns5:FurnitureFittings2023-09-3005948662ns5:WithinOneYearns5:CurrentFinancialInstruments2024-09-3005948662ns5:WithinOneYearns5:CurrentFinancialInstruments2023-09-3005948662ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2024-09-3005948662ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2023-09-3005948662ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2024-09-3005948662ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2023-09-3005948662ns5:BetweenOneFiveYears2024-09-3005948662ns5:BetweenOneFiveYears2023-09-3005948662ns5:MoreThanFiveYears2024-09-3005948662ns5:MoreThanFiveYears2023-09-3005948662ns5:AllPeriods2024-09-3005948662ns5:AllPeriods2023-09-3005948662ns5:Secured2024-09-3005948662ns5:Secured2023-09-3005948662ns5:DeferredTaxation2023-09-3005948662ns5:DeferredTaxation2024-09-3005948662ns10:OrdinaryShareClass12024-09-3005948662ns5:RetainedEarningsAccumulatedLosses2023-09-3005948662ns5:RetainedEarningsAccumulatedLosses2023-10-012024-09-30
REGISTERED NUMBER: 05948662 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2024

FOR

RADCLIFFE PHARMACY LIMITED

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


RADCLIFFE PHARMACY LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 30 SEPTEMBER 2024







DIRECTOR: Mr S Iqbal





SECRETARY: Mrs A Iqbal





REGISTERED OFFICE: 2 Cedargrove
Hagley
Stourbridge
West Midlands
DY9 0DR





REGISTERED NUMBER: 05948662 (England and Wales)





ACCOUNTANTS: Ashcrofts Accountants Limited
2 Cedargrove
Hagley
Stourbridge
West Midlands
DY9 0DR

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

BALANCE SHEET
30 SEPTEMBER 2024

2024 2023
Notes £    £   
FIXED ASSETS
Intangible assets 4 322,292 339,792
Tangible assets 5 37,170 36,297
359,462 376,089

CURRENT ASSETS
Stocks 6 94,705 138,202
Debtors 7 938,650 737,679
Cash at bank and in hand 268,774 160,524
1,302,129 1,036,405
CREDITORS
Amounts falling due within one year 8 (727,743 ) (740,276 )
NET CURRENT ASSETS 574,386 296,129
TOTAL ASSETS LESS CURRENT
LIABILITIES

933,848

672,218

CREDITORS
Amounts falling due after more than one
year

9

(342,641

)

(16,667

)

PROVISIONS FOR LIABILITIES 13 (866 ) (3,218 )
NET ASSETS 590,341 652,333

CAPITAL AND RESERVES
Called up share capital 14 100 100
Retained earnings 15 590,241 652,233
SHAREHOLDERS' FUNDS 590,341 652,333

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

BALANCE SHEET - continued
30 SEPTEMBER 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 22 May 2025 and were signed by:





Mr S Iqbal - Director


RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024


1. STATUTORY INFORMATION

Radcliffe Pharmacy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2023, is being amortised evenly over its estimated useful life of twenty years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.
Fixtures, fittings & equipment - 25% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2024


2. ACCOUNTING POLICIES - continued

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 27 (2023 - 21 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 October 2023
and 30 September 2024 350,000
AMORTISATION
At 1 October 2023 10,208
Amortisation for year 17,500
At 30 September 2024 27,708
NET BOOK VALUE
At 30 September 2024 322,292
At 30 September 2023 339,792

5. TANGIBLE FIXED ASSETS
Fixtures,
fittings
& equipment
£   
COST
At 1 October 2023 181,467
Additions 10,807
At 30 September 2024 192,274
DEPRECIATION
At 1 October 2023 145,170
Charge for year 9,934
At 30 September 2024 155,104
NET BOOK VALUE
At 30 September 2024 37,170
At 30 September 2023 36,297

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2024


6. STOCKS
2024 2023
£    £   
Stocks 94,705 138,202

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 249,218 240,116
Other debtors 660,192 390,167
VAT 24,346 100,672
Prepayments and accrued income 4,894 6,724
938,650 737,679

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts (see note 10) 23,829 10,000
Trade creditors 311,052 337,761
Social security and other taxes 3,769 1,877
Other creditors 100,905 100,602
Directors' loan accounts 285,007 285,679
Accruals and deferred income 3,181 4,357
727,743 740,276

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2024 2023
£    £   
Bank loans (see note 10) 342,641 16,667

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal 272,258 -

10. LOANS

An analysis of the maturity of loans is given below:

2024 2023
£    £   
Amounts falling due within one year or on demand:
Bank loans 23,829 10,000

Amounts falling due between one and two years:
Bank loans - 1-2 years 25,029 10,000

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2024


10. LOANS - continued
2024 2023
£    £   
Amounts falling due between two and five years:
Bank loans - 2-5 years 45,354 6,667

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal 272,258 -

11. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2024 2023
£    £   
Between one and five years 2,873 2,873
In more than five years 27,200 27,200
30,073 30,073

12. SECURED DEBTS

The following secured debts are included within creditors:

2024 2023
£    £   
Bank loans 366,470 26,667

13. PROVISIONS FOR LIABILITIES
2024 2023
£    £   
Deferred tax 866 3,218

Deferred
tax
£   
Balance at 1 October 2023 3,218
Credited during the year (2,352 )
Balance at 30 September 2024 866

14. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
100 Ordinary £1 100 100

RADCLIFFE PHARMACY LIMITED (REGISTERED NUMBER: 05948662)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2024


15. RESERVES
Retained
earnings
£   

At 1 October 2023 652,233
Deficit for the year (25,992 )
Dividends (36,000 )
At 30 September 2024 590,241

16. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

At 30 September 2024 there was a loan from Mr S Iqbal of £285,007 (2023: £285,679). This unsecured loan is interest free and repayable on demand.